

Tobias Bald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7210248/publications.pdf>

Version: 2024-02-01

51
papers

5,035
citations

186265

28
h-index

214800

47
g-index

56
all docs

56
docs citations

56
times ranked

9166
citing authors

#	ARTICLE	IF	CITATIONS
1	NKG7 Is Required for Optimal Antitumor T-cell Immunity. <i>Cancer Immunology Research</i> , 2022, 10, 154-161.	3.4	16
2	C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer. , 2022, 10, e004024.		38
3	C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma. <i>European Journal of Cancer</i> , 2022, 167, 13-22.	2.8	15
4	Plasticity of NK cells in Cancer. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	11
5	Abstract 3502: AXA-042 - a novel systemic TLR2/6 agonist for anti-tumor therapy. <i>Cancer Research</i> , 2022, 82, 3502-3502.	0.9	0
6	Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges. <i>Seminars in Cancer Biology</i> , 2022, 86, 477-490.	9.6	10
7	IFN-Î» Diminishes the Severity of Viral Bronchiolitis in Neonatal Mice by Limiting NADPH Oxidase-Induced PAD4-Independent NETosis. <i>Journal of Immunology</i> , 2022, 208, 2806-2816.	0.8	7
8	The myeloid cell type I IFN system promotes antitumor immunity over pro-tumoral inflammation in cancer T-cell therapy. <i>Clinical and Translational Immunology</i> , 2021, 10, e1276.	3.8	5
9	BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. <i>Cell</i> , 2021, 184, 2167-2182.e22.	28.9	131
10	Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy. <i>Immunity</i> , 2020, 53, 824-839.e10.	14.3	85
11	CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells. <i>Immunity</i> , 2020, 53, 805-823.e15.	14.3	79
12	The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. <i>Nature Immunology</i> , 2020, 21, 835-847.	14.5	243
13	Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma. <i>Immunity</i> , 2020, 53, 564-580.e9.	14.3	27
14	The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation. <i>Nature Immunology</i> , 2020, 21, 1205-1218.	14.5	110
15	Cancer-killing, decoy-resistant interleukin-18. <i>Immunology and Cell Biology</i> , 2020, 98, 434-436.	2.3	7
16	Innate Cancer Immunoediting. <i>Journal of Investigative Dermatology</i> , 2020, 140, 745-747.	0.7	2
17	Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis. <i>Cell Reports</i> , 2020, 30, 2512-2525.e9.	6.4	34
18	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 3671-3681.	7.0	53

#	ARTICLE	IF	CITATIONS
19	The role of NK cell as central communicators in cancer immunity. <i>Advances in Immunology</i> , 2020, 147, 61-88.	2.2	15
20	Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity. <i>Cancer Discovery</i> , 2019, 9, 1754-1773.	9.4	173
21	Hide and seek: Plasticity of innate lymphoid cells in cancer. <i>Seminars in Immunology</i> , 2019, 41, 101273.	5.6	26
22	Systematic assessment of LCMV based vaccine vectors expressing melanocyte differentiation antigens in human in vitro assays and in mouse melanoma models.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14299-e14299.	1.6	0
23	Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment. <i>Cancer Cell</i> , 2018, 33, 634-648.e5.	16.8	163
24	TGF β 2 shuts the door on T cells. <i>British Journal of Cancer</i> , 2018, 119, 1-3.	6.4	15
25	CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. <i>Journal of Clinical Investigation</i> , 2018, 128, 2613-2625.	8.2	91
26	Oncogenic-Drivers Dictate Immune Responses to Control Disease Progression in Acute Myeloid Leukaemia. <i>Blood</i> , 2018, 132, 904-904.	1.4	0
27	Genome-wide in vivo screen identifies novel host regulators of metastatic colonization. <i>Nature</i> , 2017, 541, 233-236.	27.8	194
28	Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. <i>Immunity</i> , 2017, 47, 789-802.e9.	14.3	207
29	Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. <i>Nature Immunology</i> , 2017, 18, 1004-1015.	14.5	504
30	MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. <i>Cancer Research</i> , 2017, 77, 4697-4709.	0.9	126
31	Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. <i>Cancer Research</i> , 2017, 77, 4684-4696.	0.9	80
32	Basophils Promote Tumor Rejection via Chemotaxis and Infiltration of CD8+ T Cells. <i>Cancer Research</i> , 2017, 77, 291-302.	0.9	68
33	Structural decoding of netrin-4 reveals a regulatory function towards mature basement membranes. <i>Nature Communications</i> , 2016, 7, 13515.	12.8	74
34	Phorbol ester-induced neutrophilic inflammatory responses selectively promote metastatic spread of melanoma in a TLR4-dependent manner. <i>Onc Immunology</i> , 2016, 5, e1078964.	4.6	13
35	A Preclinical Model of Malignant Peripheral Nerve Sheath Tumor-like Melanoma Is Characterized by Infiltrating Mast Cells. <i>Cancer Research</i> , 2016, 76, 251-263.	0.9	33
36	Dickkopf-3 Contributes to the Regulation of Anti-Tumor Immune Responses by Mesenchymal Stem Cells. <i>Frontiers in Immunology</i> , 2015, 6, 645.	4.8	15

#	ARTICLE	IF	CITATIONS
37	The experimental power of FR900359 to study Gq-regulated biological processes. <i>Nature Communications</i> , 2015, 6, 10156.	12.8	282
38	Differential role of cannabinoids in the pathogenesis of skin cancer. <i>Life Sciences</i> , 2015, 138, 35-40.	4.3	49
39	Self-Antigen Presentation by Keratinocytes in the Inflamed Adult Skin Modulates T-Cell Auto-Reactivity. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1996-2004.	0.7	16
40	MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. <i>Nature Communications</i> , 2015, 6, 8755.	12.8	175
41	Cannabinoid 1 receptors in keratinocytes attenuate fluorescein isothiocyanate-induced mouse atopic-like dermatitis. <i>Experimental Dermatology</i> , 2014, 23, 401-406.	2.9	27
42	Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation. <i>Cancer Discovery</i> , 2014, 4, 674-687.	9.4	226
43	Ultraviolet-radiation-induced inflammation promotes angiogenesis and metastasis in melanoma. <i>Nature</i> , 2014, 507, 109-113.	27.8	547
44	Oxidative Damage of DNA Confers Resistance to Cytosolic Nuclease TREX1 Degradation and Potentiates STING-Dependent Immune Sensing. <i>Immunity</i> , 2013, 39, 482-495.	14.3	338
45	Cannabinoid 1 Receptors in Keratinocytes Modulate Proinflammatory Chemokine Secretion and Attenuate Contact Allergic Inflammation. <i>Journal of Immunology</i> , 2013, 190, 4929-4936.	0.8	41
46	Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. <i>Nature</i> , 2012, 490, 412-416.	27.8	506
47	Neonatal UVB exposure accelerates melanoma growth and enhances distant metastases in Hgf-Cdk4 ^{R24C} C57BL/6 mice. <i>International Journal of Cancer</i> , 2011, 129, 285-294.	5.1	32
48	Peripheral lymphangiogenesis in mice depends on ectodermal connexin-26 (Gjb2). <i>Journal of Cell Science</i> , 2011, 124, 2806-2815.	2.0	13
49	Peripheral lymphangiogenesis in mice depends on ectodermal connexin-26 (Gjb2). <i>Development (Cambridge)</i> , 2011, 138, e1706-e1706.	2.5	1
50	Proteolytic processing of the serine protease matriptase-2: identification of the cleavage sites required for its autocatalytic release from the cell surface. <i>Biochemical Journal</i> , 2010, 430, 87-95.	3.7	56
51	Complete Regression of Advanced Primary and Metastatic Mouse Melanomas following Combination Chemoimmunotherapy. <i>Cancer Research</i> , 2009, 69, 6265-6274.	0.9	46